/PRNewswire/ - MYND Life Sciences Inc. (CSE: MYND) ("MYND"), a drug research and development company focused on novel psychedelic drug development, diagnostic.
MYND Life Sciences Inc Establishes Scientific Advisory Board streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Image credit: Kampmann Lab
When a single gene in a cell is turned on or off, its resulting presence or absence can affect the function and survival of the cell. In a new study appearing May 24 in
Nature Neuroscience, UCSF researchers have successfully catalogued this effect in the human neuron by separately toggling each of the 20,000 genes in the human genome.
In doing so, they’ve created a technique that can be employed for many different cell types, as well as a database where other researchers using the new technique can contribute similar knowledge, creating a picture of gene function in disease across the entire spectrum of human cells.
E-Mail
IMAGE: Super-resolution microscopy of a neuron shows the accumulation of lipids within lysosomes that occurs when the gene for prosaposin is suppressed. view more
Credit: UCSF
When a single gene in a cell is turned on or off, its resulting presence or absence can affect the function and survival of the cell. In a new study appearing May 24 in
Nature Neuroscience, UCSF researchers have successfully catalogued this effect in the human neuron by separately toggling each of the 20,000 genes in the human genome.
In doing so, they ve created a technique that can be employed for many different cell types, as well as a database where other researchers using the new technique can contribute similar knowledge, creating a picture of gene function in disease across the entire spectrum of human cells.
Dr. Andrew Singleton
Dr. Andrew B. Singleton is the director of a new NIH intramural research effort, the Center for Alzheimer’s and Related Dementias (CARD). He has been serving as CARD acting director since its construction plan launch in January 2020. He is set to stimulate and lead collaborative research group projects to expand knowledge of the biological mechanisms of Alzheimer’s and related dementias, and to explore methods of treatment and prevention.
“With his decades of experience leading cutting-edge neurodegenerative disease research, Andy is uniquely qualified to inspire and facilitate a collaborative network of multidisciplinary scientists to realize the CARD mission of initiating, stimulating, accelerating and supporting research in Alzheimer’s and related dementias,” said NIA director Dr. Richard Hodes. “I am confident that through his leadership, NIH will continue to make significant advancement toward the development of effective treatments and preve